Chemistry:Ferric derisomaltose

Short description: Medication

Ferric derisomaltose

Clinical data
Trade names	Monoferric, Monofer
Other names	FDI
AHFS/Drugs.com	Monograph
License data	US DailyMed: derisomaltose Ferric derisomaltose
Routes of administration	Intravenous
ATC code	None
Legal status
Legal status	AU: S4 (Prescription only) CA: ℞-only US: ℞-only
Identifiers
IUPAC name iron(3+);(2S,3R,4R,5R)-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexane-1,2,3,4,5-pentol
CAS Number	1345510-43-1
PubChem CID	86278348
DrugBank	DB15617
UNII	AHU547PI9H
KEGG	D11808
Chemical and physical data
Formula	C18H34FeO16+3
Molar mass	562.299 g·mol−1
3D model (JSmol)	Interactive image
SMILES C(C1C(C(C(C(O1)OCC2C(C(C(C(O2)OCC(C(C(C(CO)O)O)O)O)O)O)O)O)O)O)O.[Fe+3]
InChI InChI=1S/C18H34O16.Fe/c19-1-5(21)9(23)10(24)6(22)3-31-17-16(30)14(28)12(26)8(34-17)4-32-18-15(29)13(27)11(25)7(2-20)33-18;/h5-30H,1-4H2;/q;+3/t5-,6+,7+,8+,9+,10+,11+,12+,13-,14-,15+,16+,17-,18-;/m0./s1 Key:JTQTXQSGPZRXJF-DOJSGGEQSA-N

Ferric derisomaltose, sold under the brand name Monoferric among others, is a medication for the treatment of iron deficiency anemia in adults who have intolerance to oral iron or have had unsatisfactory response to oral iron or who have non-hemodialysis dependent chronic kidney disease (NDD-CKD). It was approved for use in the United States in January 2020. It is given intravenously.